Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study.

By Castellano, Daniel. Oncologist, 2013 . 18(1):46-53. , Formato Vancouver: Castellano D, Bajetta E, Panneerselvam A, Saletan S, Kocha W, O'Dorisio T et al. RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study. Oncologist. 2013;18(1):46-53.

Place Hold on Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study.

The role of RANK-ligand inhibition in cancer: The story of denosumab

By Castellano, Daniel | Cortés-Funes Castro, Hernán | García Escobar, Ignacio | Sepúlveda Sánchez, Juan Manuel | Rodríguez Antolín, Alfredo. Oncologist, 2011 . 16(2):136-145. , Formato Vancouver: Castellano D, Sepúlveda JM, García Escobar I, Rodriguez Antolín A, Sundlöv A, Cortés-Funes H. The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist. 2011;16(2):136-45.

Place Hold on The role of RANK-ligand inhibition in cancer: The story of denosumab

Search for 'Provider:Oncologist, and itype:ART and au:Castellano, Daniel'

Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study.

The role of RANK-ligand inhibition in cancer: The story of denosumab